Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans
PLoS ONE – December 02, 2010
Source: OpenAlex
Summary
A single dose of the classic hallucinogen psilocybin significantly reduced anxiety and depression in cancer patients. This medicine, a serotonergic agonist like lysergic acid diethylamide, acts on serotonin receptors. Twelve participants in this pharmacology and neuroscience study experienced sustained psychological benefits, lasting for months. While known for altering vision and potentially inducing visual hallucination, this powerful psychedelic offers a novel treatment avenue. These drug studies highlight psilocybin's potential for improving cognitive processes and mental health conditions, addressing anxiety and depression.
Abstract
Clinicaltrials.gov NCT00823407.